Detalles de la búsqueda
1.
Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
BJU Int
; 132(2): 188-195, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36855895
2.
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
Prostate
; 82(15): 1469-1476, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35971798
3.
Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer.
Clin Proteomics
; 19(1): 9, 2022 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35477343
4.
Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.
BJU Int
; 123(5): 826-833, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30216634
5.
Evaluation of Proclarix in the diagnostic work-up of prostate cancer.
BJUI Compass
; 5(2): 297-303, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38371198
6.
Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.
Bioorg Med Chem Lett
; 22(21): 6705-11, 2012 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23006603
7.
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
PLoS One
; 16(11): e0259093, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34767586
8.
Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
PLoS One
; 15(5): e0233442, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32421745
9.
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
PLoS One
; 12(8): e0181557, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28767721
Resultados
1 -
9
de 9
1
Próxima >
>>